Commonwealth Equity Services
CRDL

Commonwealth Equity Services’s Cardiol Therapeutics CRDL Stock Holding History

Commonwealth Equity Services’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.2K Buy
11,495
+395
+4% +$500 ﹤0.01% 4392
2026
Q1 		$15K Buy
11,100
+370
+3% +$380 ﹤0.01% 4268
2025
Q4 		$10.2K Buy
10,730
+130
+1% +$136 ﹤0.01% 4263
2025
Q3 		$11K Buy
+10,600
New +$12.9K ﹤0.01% 4221

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Commonwealth Equity Services's CRDL Position: Q2 2026 in Review

Commonwealth Equity Services increased its Cardiol Therapeutics (CRDL) stake by 3.6% in Q2 2026, buying an estimated $500 and bringing the position to 11,495 shares worth $12.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4392.

Commonwealth Equity Services first reported a position in CRDL in Q3 2025 and has held it in 4 quarters since. The position peaked at $15K in Q1 2026. 51 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

  • Commonwealth Equity Services held 11,495 shares of Cardiol Therapeutics worth $12.2K as of Q2 2026.
  • Commonwealth Equity Services bought 395 Cardiol Therapeutics shares in Q2 2026, an estimated $500.
  • Cardiol Therapeutics made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #4392 holding.
  • Commonwealth Equity Services first reported a position in Cardiol Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Commonwealth Equity Services's Cardiol Therapeutics position peaked at $15K in Q1 2026.
  • 51 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.